Bayer's US Pharma Bet: Doubling Down on America While the Farm Business Tests Investor Patience
Published on 10/07/2026 at 14:51 | Editorial boerse-global.de
Bayer's pharmaceutical ambitions now hinge on a single geography. Sebastian Guth, who runs the company's US pharma division, has told the Neue Zürcher Zeitung that the group intends to double its American business once more by the end of 2030 — a target that follows a steady climb in the region's weight, with the US share of global sales rising from 20% to roughly 35% in recent years.
Getting there will not be cheap or quick. Guth points to the long timelines and heavy capital demands of drug development, and management is watching Washington closely for potential trade barriers. No special arrangement with the US government is in place, leaving Leverkusen to weigh a range of strategic options.
Ohio as the Anchor
The most concrete piece of that strategy is a planned pharmaceutical production site in New Albany, Ohio, spanning 200 acres and carrying a price tag of USD 2.2 billion. The project is expected to generate 1,500 construction jobs and 600 permanent positions. Ohio Governor Mike DeWine has called it the state's largest international health investment.
China remains Bayer's second-largest market, backed by more than a century of presence and research partnerships with local universities.
A Stock at a Crossroads
The growth narrative has done little for the share price lately. Bayer closed yesterday at EUR 44.25, down 7.3% over seven days — a pullback that has eaten into this year's gains, though the stock is still up 20% since January. Investors are now weighing whether the current level is an entry point or simply a pause before further weakness.
Should investors sell immediately? Or is it worth buying Bayer?
The tension is easy to frame: pharma is investing for the future and reshuffling its leadership, while the crop science division keeps dragging on valuation. On October 1, Dr. Christoph Koenen took over as Chief Medical Officer, adding the role to his existing oversight of clinical development in the pharma unit. Bayer also launched the Menopause Advocacy and Policy Alliance in late September.
The Agricultural Question Mark
What matters most in the coming weeks is how much seasonal shifts and pricing pressure in crop protection are eating into group earnings. The company did buy itself breathing room by placing two hybrid bonds worth EUR 2 billion, lifting its outstanding hybrid volume to EUR 6.55 billion. The tranches carried coupons of 5.75% and 6.25% — a reminder of what that flexibility costs.
Analysts are not expecting a smooth quarter. Virginie Boucher-Ferte of Deutsche Bank Research forecast on September 29 that third-quarter 2026 operating revenue would grow 1.3% year over year, while operating profit slips 10%. JPMorgan's Richard Vosser warned the same day that early consensus for the quarter may be too optimistic, largely because of a timing effect in agriculture, though he kept his full-year estimates intact.
Pipeline Wins vs. Legal Overhang
The bull case rests on the idea that the market is undervaluing Bayer's pharma pipeline. JPMorgan reiterated an Overweight rating on October 1 with a EUR 61 target, while Deutsche Bank Research recommends the shares with a EUR 60 target. Both point to tangible clinical progress: the FDA accepted the supplemental application for Lynkuet in vasomotor symptoms associated with hormone receptor-positive breast cancer and granted a fast-track review, while BlueRock Therapeutics' cell therapy candidate Lemiretprocel received orphan-drug status from both the FDA and the EMA in late September for several inherited retinal diseases.
Against that stands the unresolved legal legacy. US court approval of the Monsanto settlement, worth a total of USD 7.25 billion, is still pending — a sword of Damocles over the balance sheet until it becomes final. European regulators added fresh headwinds after EU member states rejected indefinite approvals for crop protection products roughly a week ago.
The November 3 Verdict
Technically, the picture is finely balanced. As long as the 200-day moving average at EUR 43.16 holds, optimists can argue this is a healthy consolidation. A break below that level on renewed agricultural worries could accelerate selling toward the year's lows.
The next hard catalyst is already circled: on November 3, 2026, management will publish detailed third-quarter 2026 results. That print will show whether the agricultural timing issues were truly temporary — or whether the full-year targets need reworking. Until then, the stock's direction rests on a tug-of-war between pipeline optimism and the farm business's stubborn drag.
Ad
Bayer Stock: New Analysis - 7 October
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
